<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD), like <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD), is associated with cholinergic deficits </plain></SENT>
<SENT sid="1" pm="."><plain>Rivastigmine provides sustained, brain-selective inhibition of acetylcholinesterase and butyrylcholinesterase </plain></SENT>
<SENT sid="2" pm="."><plain>Preliminary data suggest that rivastigmine may provide significant benefits in patients with AD and cerebrovascular disease (mixed <z:hpo ids='HP_0000726'>dementia</z:hpo>), and in patients with VaD </plain></SENT>
<SENT sid="3" pm="."><plain>Open-label rivastigmine treatment has been associated with improved cognitive and functional abilities, behavioral symptoms, and reduced caregiver stress in a small pilot study in these patients </plain></SENT>
<SENT sid="4" pm="."><plain>Larger, prospective, double-blind studies of rivastigmine in patients with VaD are under way </plain></SENT>
<SENT sid="5" pm="."><plain>These studies will confirm whether rivastigmine is an efficacious treatment option for a range of patients for whom, until now, there have been few symptomatic therapies </plain></SENT>
</text></document>